157 results match your criteria: "Erythema Dyschromicum Perstans"
Disorders of hyperpigmentation and associated thyroid abnormalities: a retrospective cohort study.
Arch Dermatol Res
August 2024
Department of Dermatology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Quality of life in patients with acquired dermal macular hyperpigmentation: a systematic review.
Clin Exp Dermatol
November 2024
Chroma Dermatology, University of Melbourne, Carlton, VIC, Australia.
Article Synopsis
- * A review of existing literature found a lack of systematic studies on how these conditions impact patients' quality of life (QOL), with only seven studies meeting criteria to highlight impairment in QOL due to ADMH.
- * Overall, the studies suggest that ADMH significantly affects QOL, potentially more so than melasma and similar to or less than vitiligo, emphasizing the need for clinicians to consider the psychosocial aspects when managing patients with these conditions.
Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer.
Support Care Cancer
May 2024
Department of Dermatology, Stanford University, 450 Broadway St Pav B 4th Fl, Redwood City Palo Alto, CA, 94063, USA.
Article Synopsis
- - **Introduction to EDP and EGFRi**: Cutaneous adverse reactions to epidermal growth factor receptor inhibitors (EGFRi) are common, but dyspigmentation, particularly Erythema dyschromicum perstans (EDP), is rare and can significantly impact patient quality of life. The study aimed to document and manage EDP cases induced by EGFRi. - **Study Overview**: A multicenter retrospective review identified 16 patients with EGFRi-induced EDP from 2017 to 2023. The majority were elderly Asian females with non-small cell lung cancer, primarily treated with osimertinib, showing a median onset of EDP at 6 months. - **Results and Patient Experience**
Erythema dyschromicum perstans following influenza vaccine.
J Eur Acad Dermatol Venereol
October 2024
Department of Dermatology, Sheikh Khalifa Medical City, Abu Dhabi, UAE.
Ashy Dermatosis in a Two-year-old Child: A Case Report and Mini-review.
Acta Dermatovenerol Croat
August 2023
Eri Hotta, MD, Department of Dermatology, 101 Shimokaiinnji, Shimouchida, Nagaokakyo, Kyoto, Japan;
Article Synopsis
- Ashy dermatosis, also known as erythema dyschromicum perstans, is marked by grey patches appearing on the skin, and its exact cause is still unknown.
- A case study of a two-year-old child suggests that the condition may have developed due to an infection, with the skin improving naturally over two years without treatment.
- This case is notably the second instance of ashy dermatosis reported in children under three years old, highlighting the need for further research to identify why some cases resolve on their own while others do not.
Acquired dermal macular hyperpigmentation: an overview of the recent updates.
Int J Dermatol
December 2023
Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Article Synopsis
- * Recent proposals suggest classifying these disorders based on whether they involve contact sensitization, while dermoscopy serves as a key diagnostic and monitoring tool across these conditions.
- * Treatment options for ADMH are complex and include various topical and oral therapies, highlighting the need for more randomized controlled trials to improve treatment strategies.
Erythema dyschromicum perstans following neurotoxin injection for facial rhytides.
JAAD Case Rep
June 2023
Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, Texas.
Facial Demodicosis-Induced Skin Hyperpigmentation in an Immunocompromised Man Treated Successfully with Ivermectin 1% Cream: A Case Report.
Clin Cosmet Investig Dermatol
May 2023
Department of Dermatology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia.
Article Synopsis
- Demodex folliculorum is a common skin parasite that lives in hair follicles and sebaceous glands, and its connection to skin diseases is known, but there's little information on its role in skin pigmentation issues.
- A case study is presented about a 35-year-old Saudi male with facial hyperpigmentation caused by Demodex, who was being treated with immunosuppressive drugs.
- The patient was effectively treated with ivermectin 1% cream, showing significant improvement after three months, highlighting the need to consider Demodex as a cause of facial hyperpigmentation that can be diagnosed and managed easily.
Osimertinib-associated erythema dyschromicum perstans-like eruption: A case series.
JAAD Case Rep
May 2023
Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.
Article Synopsis
- - Erythema dyschromicum perstans (EDP) is a rare skin condition characterized by gray or blue-brown patches that affect any age or gender.
- - Diagnosis is mainly clinical, as lab tests often show nonspecific results, and existing treatments, like dapsone and phototherapy, have had limited success.
- - A case study highlighted the first successful use of topical ruxolitinib to treat EDP in a patient following their COVID-19 vaccination.
Follicular Variant of Acquired Dermal Macular Hyperpigmentation: A Case Report.
Cureus
January 2023
Dermatology, King Abdulaziz Hospital, Makkah, SAU.
Article Synopsis
- * A case study of a 55-year-old woman revealed non-scaly, brown macules on her skin that had progressively appeared over four years, leading to a diagnosis of a follicular form of ADMH after biopsy findings were evaluated.
- * Treatment involved topical steroids and tacrolimus, which showed some improvement after three months, with the patient undergoing regular follow-up appointments.
Erythema Dyschromicum Perstans After Adalimumab Treatment.
Cureus
December 2022
Dermatology, King Fahad Hospital, Madina, SAU.
Article Synopsis
- Tumor necrosis factor (TNF) is a key immune-regulating cytokine that interacts with its receptor and is important in managing diseases like inflammation, cancer, and autoimmune disorders.
- TNF-alpha blockers, such as etanercept, infliximab, and adalimumab, are used to treat various conditions, with adalimumab being a fully human monoclonal antibody approved for several inflammatory conditions.
- The paper presents a case of a male patient with psoriasis who experienced a facial skin reaction as a side effect of adalimumab treatment.
Erythema dyschromicum perstans (ashy dermatosis) unter Dimethylfumarat.
J Dtsch Dermatol Ges
November 2022
Section of Dermatology, DISSAL, University of Genoa, Ospedale-Policlinico San Martino, IRCCS, Genova, Italy.
Acquired Dermal Macular Hyperpigmentation Mimicking Dowling Degos Disease: A Case Report.
Cureus
August 2022
Dermatology, King Abdulaziz Hospital, Makkah, SAU.
Acquired dermal macular hyperpigmentation (ADMH) is a recently coined term to encompass lichen planus pigmentosus (LPP), erythema dyschromicum perstans (EDP), and Riehl's melanosis. Here we report a 60 -year- old female, with an insignificant past medical history, who presented to the dermatology clinic, with slightly itchy skin lesions on her body. The lesions were slowly increasing in number over the last 10 years.
View Article and Find Full Text PDFA rare case of erythema dyschromicum perstans arising in the setting of a third-generation tyrosine kinase inhibitor.
Acta Oncol
July 2022
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
A Case of Erythema Dyschromicum Perstans.
Dermatol Pract Concept
May 2022
Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
A Delphi consensus on the nomenclature and diagnosis of lichen planus pigmentosus and related entities.
Indian J Dermatol Venereol Leprol
January 2023
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Article Synopsis
- - Researchers conducted a Delphi exercise involving 16 experts from 12 universities in India and Australia to establish a clear definition and categorization for acquired dermal pigmentary diseases, which have been poorly defined in existing studies.
- - The consensus reached after three rounds indicated that the term 'acquired dermal macular hyperpigmentation' effectively encompasses various disorders previously known as ashy dermatosis, erythema dyschromicum perstans, and others, suggesting minimal differences among them.
- - Histopathology and dermatoscopy were agreed upon as useful diagnostic tools for these pigmentation disorders, but cannot differentiate between the individual conditions, indicating a need for wider international research to develop a more robust understanding.
Positive Antinuclear Antibody and Blaschkoid Lichen Planus Pigmentosus.
Cureus
February 2022
Dermatology, King Saud University College of Medicine, Riyadh, SAU.
Lichen planus pigmentosus is a rare variant of lichen planus. It is an acquired pigmentary disorder of unknown etiology. It is characterized by dark brown and slate gray macules and patches.
View Article and Find Full Text PDFDisorders of hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders.
J Am Acad Dermatol
February 2023
From the Department of Dermatology, Henry Ford Hospital, Detroit, Michigan. Electronic address:
Article Synopsis
- Disorders of hyperpigmentation, which can significantly impact patients' quality of life, are often challenging to diagnose due to their similar appearances and overlapping symptoms.
- The review categorizes these disorders based on where the pigment is deposited in the skin and also highlights specific conditions, while excluding genetic and systemic causes.
- The second part of the article series focuses on available medical and procedural treatments for managing hyperpigmentation.
Annular lichenoid diseases.
Clin Dermatol
December 2022
Department of Dermatology, University of Florida College of Medicine, Gainesville, Florida, USA.
Article Synopsis
- - Annular lichenoid diseases are a group of skin conditions characterized by circular or raised lesions that differ in size and quantity.
- - Some examples of these conditions include annular lichen planus, erythema multiforme, and lichen sclerosus.
- - Distinct clinical features and microscopic examination can help differentiate between the various types of annular lichenoid diseases.
Acquired Dermal Macular Hyperpigmentation: An Update.
Indian Dermatol Online J
August 2021
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Article Synopsis
- * The term is intended to unify previously distinct diseases like lichen planus pigmentosus and Riehl's melanosis, all of which share similar characteristics and treatment challenges.
- * The article aims to review recent advancements in understanding ADMH to support research and improve treatment options.
Dermoscopy of acquired pigmentary disorders: a comprehensive review.
Int J Dermatol
January 2022
Keck School of Medicine of University of Southern California, Los Angeles, California, USA.
Article Synopsis
- Dermoscopy is gaining traction not only for diagnosing skin cancers but also for evaluating various pigmentary disorders, as recent studies have shown its effectiveness in this area.
- A comprehensive review of literature from PubMed examined numerous pigmentary conditions, including melasma, vitiligo, and several others, to explore their unique dermoscopic features.
- The findings suggest that dermoscopy can help clinicians differentiate between these disorders, which can be challenging to diagnose clinically and may cause significant emotional distress for patients.
Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review.
Drug Saf
July 2021
Department of Dermatology, San Gallicano Dermatological Institute-IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
Article Synopsis
- Three cyclin-dependent kinase inhibitors (palbociclib, ribociclib, and abemaciclib) have been approved for treating advanced breast cancer in hormone receptor-positive, HER2-negative patients.
- This study aimed to assess the frequency and types of skin-related side effects experienced by patients undergoing treatment with these inhibitors.
- A review of 41 articles revealed 13 different skin reactions, highlighting the importance of managing these adverse effects to maintain patients' quality of life and treatment adherence.*